How irrational exuberance over AI could backfire
How irrational exuberance over AI could backfire
Peter Pitts
Herve Le Louet
February 21, 2020
1:26 pm

Former FDA Associate Commissioner Peter Pitts is president of the Center for Medicine in the Public Interest. Herve Le Louet is president of the Council for International Organizations of Medical Sciences.

Reframing the Debate: Why Drug Spending Can Lower Costs
Reframing the Debate: Why Drug Spending Can Lower Costs
Peter Pitts
May 4, 2016
2:15 pm

Rising healthcare costs, coupled with high-profile stories of price gouging at some small pharmaceutical companies, have left consumers feeling ripped off

What Happens Now with Off-Label Communications?
What Happens Now with Off-Label Communications?
Peter Pitts
December 1, 2015
3:00 pm

Anyone who thinks that the argument over off-label communications is just about marketing and sales is looking at the issue through very narrow blinders

Washington Insider: A New Report
Washington Insider: A New Report
Peter Pitts
August 28, 2015
2:00 pm

A report released by Public Citizen and Carleton University urges Congress to allow Medicare to negotiate innovator drug prices and introduce mandatory generic substitution for all Medicare Part D plans. And Sen. Bernie Sanders (I-Vt.) has called for “wartime powers” to break the patents on drugs. First off, allowing the feds to negotiate Part D…

FDA Policy: Is Off-Label on the Table?
FDA Policy: Is Off-Label on the Table?
Peter Pitts
April 29, 2015
2:00 pm

In years past pharma marketers had to check themselves before conveying off-label product claims, even though those off-label uses had long since become standards of care. But in recent months the FDA has signaled a willingness to open the off-label information floodgates. Former FDA Associate Commissioner Peter Pitts
explains exactly why this matters

Viewpoint: Convey Safety Info the Way Patients Want it
Viewpoint: Convey Safety Info the Way Patients Want it
Peter Pitts
January 30, 2015
12:00 pm

Safety information is knowledge. And, in the pursuit of public health, knowledge is power

Washington Insider: Mistruths and half-truths about oncology meds
Washington Insider: Mistruths and half-truths about oncology meds
Peter Pitts
October 31, 2014
4:00 am

Demonizing new treatments distracts from the real problem: policies that focus on the near-term

As I See It: Patient Centricity
As I See It: Patient Centricity
Peter Pitts
June 1, 2014
4:00 am

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

Regulatory Compliance: Social Commentary
Regulatory Compliance: Social Commentary
Peter Pitts
March 2, 2014
5:00 am

At last the FDA has offered some semblance of guidance for digital promotional activities in the medical space. Was it worth the wait? And will it change anything? Peter Pitts picks it apart

As I See It: Small is the new Big
As I See It: Small is the new Big
Peter Pitts
January 1, 2014
5:00 am

It’s fast becoming an n of 1 world, where every disease is an orphan disease and success is measured by individual outcomes

  • From Our Partners